10-10/11 :: October/November 2010
nanotimes
Companies Facts
Philips demonstrates world’s first 230V AC-powered white-light OLED modul, © Philips
of deferred revenue from the Company’s amended collaboration agreement with Alimera Sciences, Inc. In last year’s first quarter, $3.2 million of the $3.4 million of revenues resulted from revenue reco- gnition attributable to this agreement. By contrast, revenues for this year’s first quarter were primarily Retisert®
royalty payments, which resumed following
enables faster time-to-market. Moreover, it increases design freedom and expands the range of potential OLED applications.
http://www.lumiblade.com
p
Sivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release
drug delivery products for the treatment of back-of- the-eye disease including the product candidate Ilu- vien™ for the treatment of Diabetic Macular Edema, has been awarded two grants totaling $489,000 under the IRS Qualifying Therapeutic Discovery Project (QTDP). The grants were awarded to pSivida to help fund further research on new generations of the company’s drug delivery technologies targeting ophthalmic diseases.
Furthermore, the Company announced its first quarter results. Revenues for the 2010 quarter were $476,000 as compared to $3.4 million a year earlier. The change from the prior year reflects the previ- ously announced completion of the amortization
completion of an agreement with Bausch & Lomb. The Company reported a consolidated net loss of $3.1 million, or $0.17 per share, for the first quarter ended September 30, 2010, compared to a consoli- dated net loss of $1.6 million, or $0.09 per share, for the prior year’s first quarter. Cash, cash equivalents and marketable securities totaled $15.3 million at September 30, 2010 compared to $17.6 million at June 30, 2010. Net cash used of $2.3 million for the fiscal 2011 first quarter was higher than recent quar- ters as a result of a delayed payment of $500,000 of research funding received after the close of the quarter.
“Our financial resources are solid,” said Dr. Paul Ashton, President and CEO of pSivida. “Product development continues to be our primary focus, both through our collaboration with Pfizer and our inter- nal research and development. Drug delivery to the back of the eye represents a potential multi-billion dollar market opportunity for us. We are emphasi- zing the development of products using new genera- tions of our technology systems.”
http://www.psivida.com
P
VA TePla AG, Germany, a manufacturer of silicon crystallization systems as well as vacuum and
high-temperature systems, generated sales revenues of EUR95.0 million in the first nine months of 2010 (previous year: EUR98.9 million). Operating earnings
37
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79